Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Status:
Withdrawn
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of ceritinib when given together
with brentuximab vedotin to see how well they work in treating treatment-naive patients with
anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Ceritinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal
antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to
grow and spread. Giving ceritinib together with brentuximab vedotin may be a better treatment
for ALK-positive anaplastic large cell lymphoma.